AbbVie, schizophrenia

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy treatment for adults with schizophrenia did not meet the primary endpoint of showing a “statistically significant” improvement when compared with a placebo group.
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in buying Karuna Therapeutics.
AbbVie under pressure as schizophrenia drug fails two trials
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5% in early trading.
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic
Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug trial failed to meet their primary endpoint. AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily,
AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials
AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with
AbbVie's schizophrenia drug misses main goals of two trials
(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading. The drug, emraclidine,
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.
HealthDay on MSN32m
FDA Approves Cobenfy for Adults With Schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
BioPharma Dive3d
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
MedCity News4d
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test
Many currently available schizophrenia drugs work by blocking dopamine type 2 (D2) receptors. But these drugs offer limited efficacy while introducing side effects that make it hard for patients ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The Manhattan Mercury1d
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
Pearl City man who allegedly stabbed father reportedly stopped medication
HONOLULU POLICE DEPARTMENT Valentin J.R. Bigornia, 26. A 61-year-old man allegedly stabbed by his 26-year-old son in Pearl ...
Psychedelic use linked to increased risk of schizophrenia, study finds
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
psychiatryadvisor.com1d
Lower Cognitive Functioning Linked to Natural-Cause Mortality in Schizophrenia
Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.